On December 17, 2021, ASAHI KASEI CORPORATION and Shimane University announced that they had successfully developed a new coronavirus vaccine and applied for a patent.
The vaccine is based on biologically-derived materials, and the possibility of adverse reactions is extremely low.

In addition to Asahi Kasei, Shimane University was in charge of protein and inoculation experiments, Kyoto University was in charge of localization analysis in immune tissues, Mie University was in charge of tissue immunity analysis, and Institute of Tropical Medicine, Nagasaki University was in charge of virus neutralization activity analysis.
In the future, pharmaceutical companies will join it in promoting commercialization, and we plan to start manufacturing around 2023.